Výsledky vyhledávání

Akademický článek

Use of gene expression and whole-genome sequence information to improve the accuracy of genomic prediction for carcass traits in Hanwoo cattle

Autor: Sara de las Heras-Saldana, Bryan Irvine Lopez, Nasir Moghaddar, Woncheoul Park, Jong-eun Park, Ki Y. Chung, Dajeong Lim, Seung H. Lee, Donghyun Shin, Julius H. J. van der Werf

Publikováno v: Genetics Selection Evolution, Vol 52, Iss 1, Pp 1-16 (2020)

Abstract Background In this study, we assessed the accuracy of genomic prediction for carcass weight (CWT), marbling score (MS), eye muscle area (EMA) and back fat thickness (BFT) in Hanwoo cattle when using genomic best linear unbiased prediction (G

Externí odkaz: https://doaj.org/article/2f24802e0399452daaaec1e79e4c4934

Zobrazit plný text záznamu

A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers

Autor: Elizabeth H. Cull, Julie C. Martin, Wesley M. Smith, William Jeffery Edenfield, Ki Y. Chung, Mark Allen O'Rourke, William Larry Gluck, Heather Bowers

Publikováno v: Oncologist

Lessons Learned Disease control with signals of response were demonstrated, which should lead to future validating clinical trials using checkpoint inhibitors in this underserved rare malignancy population. Although the study of single types of rare

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9767f651b82c62292b4207d32046ec
https://doi.org/10.1002/onco.13798

Zobrazit plný text záznamu

NSABP C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease

Autor: Mohamed E. Salem, Shannon L Puhalla, Thomas J. George, Carmen Joseph Allegra, Bradley A. Arrick, Melanie R. Palomares, Ki Y. Chung, Michael Joseph McCormack, Asheesh Shipstone, Frederick L. Baehner, Norman Wolmark

Publikováno v: Journal of Clinical Oncology. 41:TPS284-TPS284

TPS284 Background: Detectable ctDNA after resection of early-stage solid tumors has been associated with very high risk of recurrence, suggesting ctDNA is evidence of minimal residual disease (MRD). Several studies are ongoing to investigate the role

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dab39770e326783b9e923e263fb6ac4d
https://doi.org/10.1200/jco.2023.41.4_suppl.tps284

Zobrazit plný text záznamu

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 27(19)

Purpose: We describe the first-in-human dose-escalation trial for ALRN-6924, a stabilized, cell-permeating peptide that disrupts p53 inhibition by mouse double minute 2 (MDM2) and MDMX to induce cell-cycle arrest or apoptosis in TP53-wild-type (WT) t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbbe63ad5994923a7c864f392c3bf857
https://pubmed.ncbi.nlm.nih.gov/35045962

Zobrazit plný text záznamu

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for Immunotherapy of Cancer

BackgroundCD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::222c39857b4470f6815b947401863ee2
https://jitc.bmj.com/content/9/2/e002015.full

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání